Cancers 2010, 2(4), 2100-2137; doi:10.3390/cancers2042100
Review

Treatment of Brain Metastasis from Lung Cancer

1 Department of Radiation Oncology, University of Arizona, 1501 N Campbell Ave., Tucson, AZ 85724, USA 2 Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
* Author to whom correspondence should be addressed.
Received: 9 October 2010; in revised form: 11 November 2010 / Accepted: 2 December 2010 / Published: 15 December 2010
(This article belongs to the Special Issue Organ-Specific Metastasis Formation)
PDF Full-text Download PDF Full-Text [235 KB, uploaded 15 December 2010 09:50 CET]
Abstract: Brain metastases are not only the most common intracranial neoplasm in adults but also very prevalent in patients with lung cancer. Patients have been grouped into different classes based on the presence of prognostic factors such as control of the primary tumor, functional performance status, age, and number of brain metastases. Patients with good prognosis may benefit from more aggressive treatment because of the potential for prolonged survival for some of them. In this review, we will comprehensively discuss the therapeutic options for treating brain metastases, which arise mostly from a lung cancer primary. In particular, we will focus on the patient selection for combined modality treatment of brain metastases, such as surgical resection or stereotactic radiosurgery (SRS) combined with whole brain irradiation; the use of radiosensitizers; and the neurocognitive deficits after whole brain irradiation with or without SRS. The benefit of prophylactic cranial irradiation (PCI) and its potentially associated neuro-toxicity for both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are also discussed, along with the combined treatment of intrathoracic primary disease and solitary brain metastasis. The roles of SRS to the surgical bed, fractionated stereotactic radiotherapy, WBRT with an integrated boost to the gross brain metastases, as well as combining WBRT with epidermal growth factor receptor (EGFR) inhibitors, are explored as well.
Keywords: brain metastasis; WBRT; SRS; lung cancer; PCI; neurotoxicity

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Chi, A.; Komaki, R. Treatment of Brain Metastasis from Lung Cancer. Cancers 2010, 2, 2100-2137.

AMA Style

Chi A, Komaki R. Treatment of Brain Metastasis from Lung Cancer. Cancers. 2010; 2(4):2100-2137.

Chicago/Turabian Style

Chi, Alexander; Komaki, Ritsuko. 2010. "Treatment of Brain Metastasis from Lung Cancer." Cancers 2, no. 4: 2100-2137.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert